PCN177 Trends in Canadian Oncology Health Technology Assessment

This analysis sought to examine trends in Canadian oncology health technology assessment (HTA) between 2016 and 2021, over which time the Agency for Drug Health Technology (CADTH) updated their guidelines. The pan-Canadian Oncology Review reimbursement review database was systematically searched, including all oncologic pharmaceutical submissions received by CADTH. tumor type, drug class, modelling comparative effectiveness strategies were analyzed. results presented as proportions or trends. Cochran-Armitage test used trend of categorical data assess an association a binomial ordinal (year) variable. During extraction period, 109 completed. Nineteen types represented, four most common lung (18.4%), leukemia (15.6%), lymphoma (12.8%), breast (9.2%), accounting 56% overall total. found that 43.1% antibody treatments; 59.6% modelled using partitioned survival models (PSMs), while 40.4% (semi-) Markov. Moreover, 54.1% within-trial comparisons, 52.3% included indirect 18.4% network meta-analyses (NMAs), 7.3% matched treatment comparisons (MAICs), 2.8% simulated (STCs); 13.8% naïve comparisons. Trends show significant increases (p=0.01) driven mostly NMA among MAIC STC (p=0.05), decreases seen (p=0.02). Modelling non-significant (p=0.06) towards increasing use Markov models. shows trending topics 2020 HTA. Of note, only few accounted disproportionate number submissions, PSM more prevalent strategy. Lastly, broader implementation global guidelines is suspected have influenced toward increased matching comparators.